MedTrace Logo

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

NCT07284121 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2026-04-24

No results posted yet for this study

Summary

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Conditions

  • Lung Cancer, Hepatocellular Carcinoma

Interventions

DRUG

Atezolizumab

Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2027-03-31
Completion
2028-12-31

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Italy
  • Poland
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284121 on ClinicalTrials.gov